IP Library › Patent Application 11408105
Patent Application
App. No. 11/408,105

Use of a clobetasol spray formulation to treat psoriasis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/408,105
Abstract

The present invention provides a method for treating psoriasis, by spraying onto the skin with psoriasis daily for at least 4 weeks a pharmaceutical composition containing an effective amount of clobetasol propionate. A preferred pharmaceutical composition containing clobetasol propionate, ethyl alcohol, isopropyl myristate, and anionic surfactant.

Claims (20)

1 . A method for treating psoriasis, comprising spraying onto skin afflicted with psoriasis a composition comprising an effective amount of clobetasol and a carrier containing a solvent compound and an emollient.

2 . The method of claim 1 wherein the clobetasol is clobetasol proprionate.

3 . The method of claim 1 where the composition comprises about 0.005% to about 1% by weight of clobetasol.

4 . The method of claim 1 where the composition comprises an anionic surfactant and at least one solvent compound.

5 . The method of claim 4 where the anionic surfactant is sodium lauryl sulfate.

6 . The method of claim 4 where the carrier comprises ethyl alcohol or isopropyl myristate.

7 . The method of claim 1 where the composition futher comprises ethyl alcohol, isopropyl myristate, and sodium lauryl sulfate.

8 . The method of claim 7 where the composition comprises about 0.05% by weight of clobetasol propionate.

9 . The method of claim 8 which further comprises undecyclenic acid.

10 . The method of claim 1 wherein the carrier comprises a solvent compound and an emollient compound in a ratio on a weight basis of between 5:1 and 1:5.

11 . The method of claim 10 wherein the ratio is between 3:1 and 1:3.

12 . The method of claim 1 where the composition comprises 0.05% by weight of clobetasol propionate, 49.25% by weight of 92.8% ethanol, 50.30% by weight of isopropyl myristate, and 0.1% by weight of sodium lauryl sulfate.

13 . The method of claim 1 wherein the composition is sprayed onto the afflicted skin daily for at least 4 weeks.

14 . The method of claim 1 wherein the composition is substantially free of zinc pyrithione.

15 . A pharmaceutical composition comprising clobetasol propionate, ethyl alcohol, isopropyl myristate, and anionic surfactant, wherein the composition is substantially free of zinc pyrithione.

16 . The pharmaceutical composition of claim 15 which comprises 0.05% by weight of clobetasol propionate, 49.25% by weight of 92.8% ethyl alcohol, 50.30% by weight of isopropyl myristate, and 0.1% by weight of sodium lauryl sulfate.

17 . The pharmaceutical composition of claim 16 which comprises undecyclenic acid.

18 . Use of a composition comprising clobetasol propionate, an anionic surfactant, ethyl alcohol, and isopropyl myristate for the preparation of a medicinal product for treating psoriasis characterized in that the composition is sprayed onto skin with psoriasis.

19 . The use of the composition of claim 18 comprising 0.05% by weight of clobetasol propionate, 49.25% by weight of 92.8% ethyl alcohol, 50.30% by weight of isopropyl myristate, and 0.1% by weight of sodium lauryl sulfate.

20 . The use of the composition of claim 18 , wherein the composition is sprayed onto the skin with psoriasis daily for at least 4 weeks.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS NORTH AMERICA; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.; ATON PHARMA, INC.
Reel/Frame 025950/0048 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: ATON PHARMA, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; VALEANT PHARMACEUTICALS INTERNATIONAL; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2006
From: DOW, GORDON J.
To: DOW PHARMACEUTICAL SCIENCES; DERMALOGIX PARTNERS, INC.
Reel/Frame 017671/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2006
From: STEWART, DANIEL M.
To: DOW PHARMACEUTICAL SCIENCES; DERMALOGIX PARTNERS, INC.
Reel/Frame 017671/0082 →